查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993055

基因轉移技術市場：2026-2032年全球市場預測（按基因載體類型、產品類型、技術、治療應用和最終用戶分類）

Gene Delivery Technologies Market by Delivery Vector Type, Product, Technology, Therapeutic Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因傳遞技術市場價值將達到 57.2 億美元，到 2026 年將成長到 66.2 億美元，到 2032 年將達到 155.6 億美元，複合年成長率為 15.36%。

主要市場統計數據
基準年 2025 57.2億美元
預計年份：2026年 66.2億美元
預測年份 2032 155.6億美元
複合年成長率 (%) 15.36%

對目前影響基因遞送技術創新臨床應用和商業化的科學、監管和營運因素進行策略概述。

基因遞送技術處於分子醫學、先進材料科學和精準藥物研發的交叉領域。載體設計、奈米顆粒工程和細胞操控技術的最新進展極大地改變了基因導入、修飾和抑制策略的可能性。因此，藥物發現過程得以縮短，轉化途徑更加模組化，治療方法能夠以更高的可預測性從研究階段過渡到臨床試驗階段。

對科學進步、製造成熟度和不斷變化的監管要求之間的融合進行敏銳的分析，這些融合正在重塑競爭格局和臨床策略。

基因遞送領域正經歷著許多變革，這些變革正在重新定義技術的可行性和商業性機會。首先，平台多樣化正在加速。開發人員正在努力平衡病毒載體的傳統優勢與非病毒載體方法所提供的靈活性和有效載荷柔軟性，從而建立一個更多元化的生態系統。雖然這種多樣化降低了某些治療領域的技術門檻，但也為比較分析和產品差異化帶來了新的複雜性。

重點評估 2025 年關稅調整和貿易政策趨勢將如何推動整個價值鏈的供應鏈重組、籌資策略和業務永續營運。

影響跨境貿易和進口關稅的政策發展將對基因遞送領域相關企業的供應鏈、試劑採購和資本配置產生重大的下游影響。美國2025年實施的關稅調整的累積效應，導致企業對籌資策略和供應商多元化計畫的審查增加。為此，研發企業和供應商正在重新評估供應商所在地，選擇關稅較低地區的替代供應商，並考慮將關鍵組件和試劑的生產外包到近岸地區，以降低成本波動和交貨風險。

對遞送載體、治療應用、產品類型、終端用戶需求和核心技術如何相互交織以塑造策略選擇和價值提案進行詳細分析。

市場細分為比較技術選項、臨床應用、產品需求、終端用戶趨勢和基本遞送機制提供了一個實用的觀點。就遞送載體類型而言，市場可分為非病毒載體和病毒載體兩大類。非病毒載體可細分為脂質奈米顆粒平台、物理方法和聚合物載體，其中物理方法涵蓋電穿孔、顯微注射和超音波技術。病毒載體則根據其骨架和生物學特性進行區分，腺結合病毒、腺病毒、慢病毒和逆轉錄病毒各自具有不同的風險效益比和有效載荷特徵。

對臨床能力、法規環境和生產趨勢的區域評估決定了進入全球市場的途徑和策略夥伴關係。

區域趨勢對三大主要地區的技術應用、監管路徑和商業策略產生了顯著影響。在美洲，臨床開發、先進製造能力和投資活動已形成一個密集的生態系統，支持從早期概念驗證到後期臨床項目的快速過渡。這種環境促進了研發人員與契約製造合作夥伴之間的密切合作，同時也加劇了對專業製造能力和人才的競爭。

對決定該產業競爭定位、聯盟形成和收購理由的策略原型、聯盟行為和供應商模式進行分析整合。

該產業的企業行為展現出不同的策略原型，這些原型影響著合作模式、競爭動態和創新軌跡。大規模綜合研發公司往往優先考慮平台主導地位和垂直整合，投資內部生產能力和專有給藥技術，以保持差異化優勢並管理監管風險。中型專業公司通常專注於特定適應症或專有給藥技術創新，利用與契約製造和學術合作夥伴的定向合作來節省資金，同時加速轉化階段。

旨在協調基因遞送領域的科學創新與製造韌性、監管準備和永續商業性實施的實用、優先和策略性行動。

產業領導企業應採取一系列切實可行的措施，將科學進步轉化為永續的競爭優勢。首先，在研發早期階段就應將載體選擇與長期生產和監管策略結合。透過將可生產性和監管要求納入早期載體設計，企業可以降低代價高昂的重新設計風險，並加速臨床試驗的準備。其次，應實現供應商網路多元化，並確保關鍵試劑和組件的替代來源，以減少貿易中斷和對單一故障點的依賴。

對用於得出實用見解和策略建議的主要和次要調查方法、專家訪談和檢驗方法進行透明的解釋。

本分析所依據的研究透過系統性地回顧一手資料、訪談專家以及對技術文獻進行系統性檢驗，確保了其結論的可靠性和可操作性。一手資料收集包括對研發部門高階領導、製造專家和監管專家的定向訪談，揭示了實際應用中的限制和新興實踐。此外，我們還對同行評審文章、會議論文集和技術白皮書進行了嚴格的評估，以檢驗技術趨勢並確定可複現的性能聲明，從而補充了這些定性見解。

簡要概述強調需要整合技術、營運和監管策略，將基因遞送技術的創新轉化為永續的臨床和商業性成果。

總而言之，隨著科學進步與營運和監管的日益成熟相融合，基因遞送技術正處於一個關鍵的十字路口。遞送平台的多樣化、生產模式的演變以及政策環境的變化，都要求研發、供應鏈和商業化等各個環節的組織做出謹慎而全面的選擇。那些積極主動地將載體選擇與可生產性相結合、確保穩健的供應鏈並儘早與監管機構和支付方展開對話的組織，將更有能力將技術潛力轉化為永續的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：基因轉移技術市場（依遞送載體類型分類）

  • 非病毒載體
    • 脂質奈米顆粒
    • 物理方法
      • 電穿孔
      • 顯微注射
      • 超音波
    • 基於聚合物的載體
  • 病毒載體
    • 腺結合病毒
    • 腺病毒
    • 慢病毒
    • 逆轉錄病毒

第9章 基因轉殖技術市場：依產品分類

  • 裝置
  • 成套工具
  • 試劑

第10章 基因轉殖技術市場：依技術分類

  • 轉導
  • 轉染

第11章：依治療應用分類的基因轉殖技術市場

  • 循環系統治療
  • 遺傳性疾病
  • 腫瘤學
  • 疫苗

第12章 基因轉殖技術市場：依最終用戶分類

  • 醫院和診所
  • 製藥公司
  • 研究機構

第13章 基因轉殖技術市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 基因轉殖技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 基因技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國基因技術市場

第17章：中國基因技術市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 4D Molecular Therapeutics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bluebird Bio, Inc.
  • Catalent, Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • GenScript Biotech Corporation
  • Hoffmann-La Roche AG
  • Horizon Discovery Group Co.
  • Intellia Therapeutics, Inc.
  • Lonza Group AG
  • Merck KGaA
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer Inc.
  • Promega Corporation
  • QIAGEN NV
  • Sarepta Therapeutics, Inc.
  • Sartorius AG
  • SignaGen Laboratories, LLC
  • SIRION Biotech GmbH
  • Spark Therapeutics, Inc.
  • System Biosciences, LLC
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vectalys SAS
Product Code: MRR-1A1A064C021C

The Gene Delivery Technologies Market was valued at USD 5.72 billion in 2025 and is projected to grow to USD 6.62 billion in 2026, with a CAGR of 15.36%, reaching USD 15.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.72 billion
Estimated Year [2026] USD 6.62 billion
Forecast Year [2032] USD 15.56 billion
CAGR (%) 15.36%

A strategic overview that frames current scientific, regulatory, and operational forces shaping the translation and commercialization of gene delivery innovations

Gene delivery technologies are at the intersection of molecular medicine, advanced materials science, and precision therapeutics development. Recent advances in vector design, nanoparticle engineering, and cellular manipulation techniques have driven a step-change in what is feasible for gene addition, correction, and suppression strategies. As a result, discovery funnels are shortening and translational pathways are becoming more modular, enabling a wider range of therapeutic modalities to move from bench to clinic with greater predictability.

At the same time, regulatory authorities and clinical stakeholders are increasingly focused on product quality attributes that influence safety, manufacturability, and long-term durability. This dual focus on innovation and regulatory readiness is reshaping how developers prioritize platform investments, choose delivery modalities, and structure clinical programs. Notably, logistical considerations such as cold chain, manufacturing scale, and supply resilience are now central to go-to-market planning rather than being treated as downstream operational challenges.

Consequently, organizations that align vector selection, analytical control strategies, and manufacturing scale-up early in development are positioned to reduce translational friction. This introduction sets the stage for an executive-level appraisal of disruptive shifts, policy influences, segmentation nuances, regional dynamics, and practical recommendations that follow in the subsequent sections.

An incisive analysis of converging scientific advances, manufacturing maturation, and evolving regulatory expectations that are reshaping competition and clinical strategies

The landscape of gene delivery is undergoing several transformative shifts that are redefining technical feasibility and commercial opportunity. First, platform diversification has accelerated: developers are balancing the classical strengths of viral vectors with the agility and payload flexibility offered by non-viral approaches, creating a more pluralistic ecosystem. This diversification has lowered technical barriers for some therapeutic areas while introducing new complexity around comparative analytics and product differentiation.

Second, material science breakthroughs-particularly in lipid nanoparticle formulation and polymer chemistry-are enabling finer control of biodistribution and immune engagement. These advances increase the probability of therapeutic success for indications previously considered inaccessible to gene-based interventions. Third, integrated manufacturing models and the maturation of contract development and manufacturing organizations have improved the throughput and reliability of vector production, although capacity constraints remain a practical choke point for rapid scale-up.

Finally, shifts in regulatory expectations and payer engagement models are promoting earlier alignment on clinical endpoints, safety monitoring, and post-approval evidence generation, which in turn influences preclinical modeling and trial design. Taken together, these shifts are not isolated; they interact dynamically to reshape cost structures, partner selection, and the relative attractiveness of therapeutic targets.

A focused evaluation of how 2025 tariff adjustments and trade policy dynamics are driving supply chain restructuring, procurement strategies, and operational resilience across the value chain

Policy moves affecting cross-border trade and import duties can have pronounced downstream effects on supply chains, reagent sourcing, and capital deployment for organizations working in gene delivery. In 2025, the cumulative impact of tariff adjustments introduced in the United States has amplified scrutiny on procurement strategies and supplier diversification plans. Developers and suppliers have responded by reassessing supplier footprints, qualifying alternate vendors in lower-tariff jurisdictions, and exploring nearshoring for critical components and reagents to mitigate cost volatility and delivery risk.

These adjustments are affecting different parts of the value chain unevenly. For instrument and equipment suppliers that rely on global component sourcing, tariff-induced cost pressure has prompted renegotiations of supply contracts and, in some cases, deferred capital investment decisions. For reagent and consumable providers, the need to preserve competitiveness has accelerated consolidation discussions and strategic partnerships that can preserve scale economics. Clinical trials and translational programs have also felt secondary effects; procurement delays and elevated costs for specialty reagents can slow timelines and require budgetary reallocation.

In response, forward-looking organizations are recalibrating sourcing strategies, building multi-supplier qualification pathways, and investing in supply chain visibility tools to maintain continuity. While tariffs introduce an element of cost uncertainty, they also serve as a catalyst for operational resilience, prompting strategic decisions that will influence competitive positioning over the medium term.

A nuanced exploration of how delivery vectors, therapeutic applications, product types, end-user demands, and core technologies intersect to shape strategic choices and value propositions

Segmentation provides a practical lens to compare technology choices, clinical applications, product needs, end-user dynamics, and fundamental delivery mechanisms. When considering delivery vector type, the market divides between Non-Viral Vector approaches and Viral Vector approaches. Within Non-Viral Vector approaches there is further granularity across Lipid Nanoparticle platforms, Physical Methods, and Polymer-Based Vectors, with the Physical Method category itself spanning Electroporation, Microinjection, and Ultrasound techniques. Viral Vector approaches are differentiated by backbone and biology, with Adeno Associated Virus, Adenovirus, Lentivirus, and Retrovirus serving distinct risk-benefit and payload profiles.

Therapeutic application segmentation highlights distinct development priorities for Cardiovascular Therapies, Genetic Disorders, Oncology, and Vaccines, each with unique clinical endpoints, regulatory considerations, and commercialization pathways. Product segmentation encompasses Instruments, Kits, and Reagents, reflecting divergent revenue models, customer bases, and quality control requirements. End-user segmentation captures demand-side heterogeneity among Hospitals and Clinics, Pharmaceutical Companies, and Research Institutes, each of which imposes different procurement cycles, service expectations, and scale needs. Technology segmentation distinguishes between Transduction and Transfection methods, which drive differing assay development approaches, safety considerations, and manufacturing controls.

Understanding how these segmentation axes intersect is essential for strategic positioning. For example, an organization focused on oncology vaccines must align vector choice, reagent quality, and clinical logistics differently than a developer pursuing systemic gene correction for a rare genetic disorder. Similarly, suppliers of instruments must tailor go-to-market models to the cadence and procurement sophistication of hospitals versus research institutes.

A regionally differentiated assessment of clinical capabilities, regulatory environments, and manufacturing trends that determine adoption pathways and strategic partnerships across global markets

Regional dynamics markedly influence technology adoption, regulatory pathways, and commercial strategies across the three principal geographies. The Americas exhibit a dense ecosystem of clinical development, advanced manufacturing capacity, and investor activity that supports rapid translation from early-stage proofs of concept to late-stage clinical programs. This environment fosters close collaboration between developers and contract manufacturing partners, although it also increases competition for specialized manufacturing capacity and qualified talent pools.

Europe, Middle East & Africa present a fragmented regulatory landscape that nonetheless offers deep expertise in translational research and a strong tradition of public-private partnership models. Regulatory harmonization efforts and collaborative networks help facilitate multinational trials, but developers must navigate diverse reimbursement frameworks and regional infrastructure variability. In several jurisdictions, progressive policy initiatives are accelerating the adoption of gene therapies within national health systems, while in others, access remains constrained by budgetary and delivery considerations.

Asia-Pacific demonstrates rapidly expanding technical capabilities, growing manufacturing capacity, and strong public sector investment in biotech infrastructure. Several markets in the region are advancing local regulatory frameworks to accommodate complex biologics and cell and gene therapies, creating opportunities for clinical trial acceleration and cost-efficient manufacturing. Across all regions, cross-border partnerships, technology transfer, and local talent development will be decisive factors in scaling successful gene delivery platforms.

An analytical synthesis of strategic archetypes, partnership behaviors, and supplier models that determine competitive positioning, alliance formation, and acquisition rationale in the sector

Company behavior across the sector reveals distinct strategic archetypes that influence partnership patterns, competitive dynamics, and innovation trajectories. Large integrated developers tend to prioritize platform control and vertical integration, investing in in-house manufacturing capabilities and proprietary delivery technologies to protect differentiation and manage regulatory risk. Mid-sized specialty firms often focus on niche indications or unique delivery innovations, using targeted collaborations with contract manufacturers and academic partners to accelerate translational steps while conserving capital.

Suppliers of instruments, kits, and reagents frequently pursue dual strategies of technological incrementality and service expansion, enhancing product portfolios with automation, analytics, and quality management solutions to deepen customer relationships. Partnerships between technology innovators and established pharmaceutical companies are increasingly common, reflecting mutual needs: innovators bring novel delivery platforms and early-stage clinical data, while larger firms contribute regulatory, commercialization, and distribution expertise.

Additionally, a growing number of academic spinouts and biotech startups are capitalizing on platform-agnostic approaches that can be licensed across therapeutic domains. These entities often collaborate with specialized contract research and manufacturing organizations to de-risk clinical development. Observing these patterns can inform competitive positioning, alliance strategies, and potential acquisition targets for stakeholders seeking to accelerate capability-building or to augment existing pipelines.

Practical and prioritized strategic actions designed to align scientific innovation with manufacturing resilience, regulatory readiness, and sustainable commercial execution in gene delivery

Industry leaders should adopt a set of pragmatic actions to convert scientific progress into sustainable competitive advantage. First, align vector selection with long-term manufacturing and regulatory strategies early in the development process. By integrating manufacturability and regulatory requirements into early-stage vector design, organizations reduce the risk of costly redesigns and expedite clinical readiness. Second, diversify supplier networks and qualify alternate sources for critical reagents and components to lessen exposure to trade disruptions or single-point failures.

Third, invest in cross-functional capabilities that bridge R&D, regulatory affairs, and commercial teams so that clinical trial design reflects end-user needs and payer expectations. This alignment increases the probability that clinical endpoints translate into meaningful adoption. Fourth, pursue strategic partnerships that combine complementary strengths-platform innovation, clinical development expertise, or global commercialization reach-rather than duplicative capabilities. Fifth, prioritize data robustness and standardized analytics across modalities to facilitate comparative decision-making and to support regulatory submissions.

Finally, consider staged capital allocation that balances platform development with investments in manufacturing resilience and supply chain transparency. Taken together, these actions will help organizations navigate technical complexity, regulatory scrutiny, and market access hurdles while positioning them to capture downstream value from successful therapeutic programs.

A transparent description of the combined primary and secondary research methods, expert interviews, and triangulation approaches used to derive actionable insights and strategic recommendations

The research underpinning this analysis combined a structured review of primary sources, expert interviews, and systematic triangulation of technical literature to ensure robust, actionable findings. Primary data collection included targeted interviews with senior R&D leaders, manufacturing experts, and regulatory professionals to surface real-world constraints and emergent practices. These qualitative insights were complemented by a rigorous assessment of peer-reviewed publications, conference proceedings, and technical white papers to validate technological trendlines and identify reproducible performance claims.

Analytical methods emphasized cross-validation: multiple independent sources were used to confirm observations about vector performance, manufacturing bottlenecks, and clinical strategy. The research team used thematic coding to synthesize interview content and to detect recurring operational themes, which informed the recommended actions and segmentation insights. Limitations were explicitly acknowledged, particularly where emerging technologies have limited public clinical data or where commercial confidentiality constrains detail. To mitigate these gaps, the study prioritized trend consistency and corroborated supplier and developer statements with technical benchmarking where available.

The resulting methodology balances depth and breadth, delivering a synthesis that is both grounded in primary stakeholder perspectives and anchored to the technical literature necessary for strategic decision-making.

A concise synthesis emphasizing the need for integrated technical, operational, and regulatory strategies to translate gene delivery innovation into durable clinical and commercial outcomes

In summary, gene delivery technologies stand at a pivotal juncture where scientific advances are increasingly matched by operational and regulatory sophistication. The interplay between diversified delivery platforms, evolving manufacturing paradigms, and shifting policy environments requires organizations to make deliberate, integrated choices across development, supply chain, and commercialization domains. Those that proactively align vector selection with manufacturability, secure resilient supply chains, and engage regulators and payers early are better positioned to translate technical promise into durable therapeutic impact.

Moreover, regional nuances and tariff-induced supplier strategies underscore the importance of geographic flexibility and partnership-driven scale. Suppliers and developers that can demonstrate consistent quality, predictable delivery, and clear clinical value propositions will find favorable opportunities across different markets. Ultimately, navigating this complex environment demands both technical excellence and strategic foresight: by combining rigorous R&D with disciplined operational planning, stakeholders can accelerate clinical translation while managing the practical realities of cost, capacity, and regulatory compliance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Delivery Technologies Market, by Delivery Vector Type

  • 8.1. Non-Viral Vector
    • 8.1.1. Lipid Nanoparticle
    • 8.1.2. Physical Method
      • 8.1.2.1. Electroporation
      • 8.1.2.2. Microinjection
      • 8.1.2.3. Ultrasound
    • 8.1.3. Polymer Based Vector
  • 8.2. Viral Vector
    • 8.2.1. Adeno Associated Virus
    • 8.2.2. Adenovirus
    • 8.2.3. Lentivirus
    • 8.2.4. Retrovirus

9. Gene Delivery Technologies Market, by Product

  • 9.1. Instruments
  • 9.2. Kits
  • 9.3. Reagents

10. Gene Delivery Technologies Market, by Technology

  • 10.1. Transduction
  • 10.2. Transfection

11. Gene Delivery Technologies Market, by Therapeutic Application

  • 11.1. Cardiovascular Therapies
  • 11.2. Genetic Disorders
  • 11.3. Oncology
  • 11.4. Vaccines

12. Gene Delivery Technologies Market, by End User

  • 12.1. Hospitals And Clinics
  • 12.2. Pharmaceutical Companies
  • 12.3. Research Institutes

13. Gene Delivery Technologies Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gene Delivery Technologies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gene Delivery Technologies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gene Delivery Technologies Market

17. China Gene Delivery Technologies Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 4D Molecular Therapeutics, Inc.
  • 18.6. Bio-Rad Laboratories, Inc.
  • 18.7. Bluebird Bio, Inc.
  • 18.8. Catalent, Inc.
  • 18.9. CRISPR Therapeutics AG
  • 18.10. Danaher Corporation
  • 18.11. GenScript Biotech Corporation
  • 18.12. Hoffmann-La Roche AG
  • 18.13. Horizon Discovery Group Co.
  • 18.14. Intellia Therapeutics, Inc.
  • 18.15. Lonza Group AG
  • 18.16. Merck KGaA
  • 18.17. Novartis AG
  • 18.18. Oxford Biomedica plc
  • 18.19. Pfizer Inc.
  • 18.20. Promega Corporation
  • 18.21. QIAGEN N.V.
  • 18.22. Sarepta Therapeutics, Inc.
  • 18.23. Sartorius AG
  • 18.24. SignaGen Laboratories, LLC
  • 18.25. SIRION Biotech GmbH
  • 18.26. Spark Therapeutics, Inc.
  • 18.27. System Biosciences, LLC
  • 18.28. Takara Bio Inc.
  • 18.29. Thermo Fisher Scientific Inc.
  • 18.30. Vectalys SAS

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY POLYMER BASED VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY POLYMER BASED VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY POLYMER BASED VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TRANSDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TRANSDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TRANSDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 168. GCC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. GCC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 170. GCC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 171. GCC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 195. G7 GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 196. G7 GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 197. G7 GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. G7 GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 204. NATO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 205. NATO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 206. NATO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 207. NATO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DELIVERY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHOD, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)